CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicThe Immunotherapy Revolution in the Management of Gynecological Cancers: From Preclinical Data to Clinical Results and Mechanisms of ImmunoresistanceView all articles
Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report
Provisionally accepted
- 1Shaoxing People's Hospital, Shaoxing, China
- 2Shaoxing Second Hospital, Shaoxing, China
- 3Ganyu District People's Hospital of Lianyungang City, Lianyungang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cervical cancer is the fourth most prevalent oncological condition affecting the global female population in 2022, considering both disease occurrence and fatality rates. Although surgical intervention is the curative approach for early stage cervical cancer, recurrent progression is associated with unfavorable clinical outcomes. The current therapeutic protocols outlined in the National Comprehensive Cancer Network Guidelines 4.2025 edition propose that for second-line or subsequent therapies of cervical carcinoma, prioritized protocols incorporate pembrolizumab administration specifically for patients demonstrating high tumor mutational burden characteristics, positive for programmed cell death ligand 1 expression, or exhibiting microsatellite instability-high/mismatch repair deficiency molecular profiles. Other proposed therapeutic approaches include bevacizumab, paclitaxel, and nanoparticle albumin-bound paclitaxel (nab-paclitaxel). To date, no standardized systemic combination protocol has been established for the management of recurrent/metastatic cervical carcinoma after first-line treatment. The clinical application of camrelizumab combined with nab-paclitaxel as a second-line intervention for recurrent human papillomavirus (HPV)-associated cervical cancer remains rare in existing medical literature. This case report documents complete remission achieved through second-line camrelizumab combined with nab-paclitaxel therapy in a 65-year-old Chinese female with recurrent HPV-associated cervical cancer with positive programmed cell death ligand 1 (PD-L1) in whom initial treatment failed. Clinical outcomes included the disease-free survival of 22 months, accompanied by the first progression-free survival (PFS1) of 10 months and the PFS2 of 58 months. The overall survival was recorded at 92 months. The patient continues to undergo active clinical surveillance. Our case report This is a provisional file, not the final typeset article illustrates that second-line immunochemotherapy utilizing camrelizumab in combination with nab-paclitaxel exhibits notable efficacy and manageable safety profile.
Keywords: cervical cancer, Human papillomavirus, Second-line therapy, camrelizumab, nanoparticle albumin-bound paclitaxel
Received: 05 Aug 2025; Accepted: 19 Nov 2025.
Copyright: © 2025 Sun, Lang, Wu, Shi, Sang and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhongkui Xiong, xiongzk@yeah.net
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.